Story perspectives

Breakthrough Study Targets Dormant Breast Cancer Cells

9/10/2025

38 7

Summary

Story summary

Researchers at the University of Pennsylvania detected and treated dormant breast cancer cells, lowering relapse risk.
In a clinical trial, 80% of participants cleared dormant cells, with over 90% disease-free after three years.
Dormant cells, or minimal residual disease (MRD), evade standard imaging and can cause metastatic cancer.
The study utilized FDA-approved drugs targeting autophagy and mTOR signaling to treat MRD effectively.
Larger studies, ABBY and PALAVY trials, aim to confirm these results.

1 of 1

Story summary

Researchers at the University of Pennsylvania detected and treated dormant breast cancer cells, lowering relapse risk.
In a clinical trial, 80% of participants cleared dormant cells, with over 90% disease-free after three years.
Dormant cells, or minimal residual disease (MRD), evade standard imaging and can cause metastatic cancer.
The study utilized FDA-approved drugs targeting autophagy and mTOR signaling to treat MRD effectively.
Larger studies, ABBY and PALAVY trials, aim to confirm these results.